RxDoctor Payments Data

Don Tran, MD

Internal Medicine · San Jose, CANPI 1881688950

Payments from drug & device makers

$2,966in general payments, 2019–2025

Across 112 payments — averaging $26.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$415
  • Amarin Pharma, Inc.$325
  • Novo Nordisk$271
  • Amgen$252
  • GSK$235
  • Sunovion Pharmaceuticals Inc.$219
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,90798%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,966 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$91,445
Medicare patients
145
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$30,256
JardianceEmpagliflozin21$20,493
ZenpepLipase/Protease/Amylase12$18,359
JanuviaSitagliptin Phosphate20$13,144
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,700
Spiriva RespimatTiotropium Bromide22$12,103
VascepaIcosapent Ethyl28$11,645
FarxigaDapagliflozin Propanediol11$11,471
LinzessLinaclotide15$8,791
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$8,402
Incruse ElliptaUmeclidinium Bromide13$4,783
Atorvastatin Calcium571$4,639
Qvar RedihalerBeclomethasone Dipropionate15$3,723
Dexlansoprazole DrDexlansoprazole12$3,598
Enalapril Maleate169$3,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$125$32,59543 claims
PfizerEliquis$20$30,25634 claims
GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta$235$19,78345 claims
Aimmune Therapeutics, Inc.Zenpep$64$18,35912 claims
MerckJanuvia$61$13,14420 claims
AstraZenecaFarxiga$124$11,47111 claims
AbbVieLinzess$415$8,79115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →